Opposing and hierarchical roles of leukotrienes in local innate immune versus vascular responses in a model of sepsis

被引:52
作者
Benjamim, CF
Canetti, C
Cunha, FQ
Kunkel, SL
Peters-Golden, M
机构
[1] Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA
[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, BR-14049 Ribeirao Preto, SP, Brazil
关键词
D O I
10.4049/jimmunol.174.3.1616
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The 5-lipoxygenase (5-LO)-derived leukotrienes (LTs) influence both local innate immunity and vascular responses, but the relative importance of effects on these two processes in sepsis is unknown. In a cecal ligation and puncture model of peritonitis with severe sepsis, 5-LO-/- mice showed a reduction in peritoneal neutrophil accumulation and an increase in the number of bacteria in the peritoneal cavity. Despite this impairment of local innate immunity, the null mice exhibited a marked improvement in survival, and this protection was also seen in wild-type animals treated with the LT synthesis inhibitor MK 886. A survival advantage in severe sepsis was also observed in mice treated with the cysteinyl-LT receptor antagonist MK 571, but not with the LTB4 receptor antagonist CP 105, 696. Protection in the 5-LO-/- mice was associated with reduced vascular leak and serum lactate levels. Moreover, wild-type mice treated with MK 571 exhibited less sepsis-induced hypotension. These data demonstrate opposing effects of cysteinyl-LTs on innate immune vs hemodynamic responses, demonstrating protective effects on local immunity and deleterious effects on the vasculature. They also suggest the possible therapeutic utility of targeting vascular events in sepsis with cysteinyl-LT blockade.
引用
收藏
页码:1616 / 1620
页数:5
相关论文
共 38 条
  • [1] INVESTIGATION OF THE INHIBITORY EFFECTS OF PGE(2) AND SELECTIVE EP AGONISTS ON CHEMOTAXIS OF HUMAN NEUTROPHILS
    ARMSTRONG, RA
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (07) : 2903 - 2908
  • [2] Bailie MB, 1996, J IMMUNOL, V157, P5221
  • [3] BAKER CC, 1983, SURGERY, V94, P331
  • [4] Septic mice are susceptible to pulmonary aspergillosis
    Benjamim, CF
    Hogaboam, CM
    Lukacs, NW
    Kunkel, SL
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (06) : 2605 - 2617
  • [5] Sepsis and evolution of the innate immune response
    Beutler, B
    Poltorak, A
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : S2 - S6
  • [6] Sepsis: A new hypothesis for pathogenesis of the disease process
    Bone, RC
    Grodzin, CJ
    Balk, RA
    [J]. CHEST, 1997, 112 (01) : 235 - 243
  • [7] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [8] PHARMACOLOGICAL STUDY OF SRS-A ON BOVINE CUTANEOUS VASCULATURE
    BURKA, JF
    EYRE, P
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1977, 55 (04) : 904 - 908
  • [9] Byrum RS, 1999, J IMMUNOL, V163, P6810
  • [10] Effects of MK-886, a leukotriene biosynthesis inhibitor, in a rabbit model of endotoxic shock
    Can, C
    Çinar, MG
    Ülker, S
    Evinç, A
    Kosay, S
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 350 (2-3) : 223 - 228